相关实验视频
Updated: Jun 1, 2026
07:46
Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
Published on: October 16, 2010
口服治疗改善了冠状动脉疾病患者的内皮功能
M Shechter1, M Sharir, M J Labrador
1Preventive & Rehabilitative Cardiac Center and the Atherosclerosis Research Center, Cedars-Sinai Burns and Allen Research Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. shechtes@netvision.net.il
Circulation
|November 9, 2000
概括
补充剂在稳定的冠状动脉疾病 (CAD) 患者中改善了内皮功能和运动耐受性. 这种口服疗法在研究小组中增强了手臂动脉血管扩张和运动能力.
科学领域:
- 心血管医学 心血管医学
- 营养科学 营养科学
- 身体生理学 身体生理学
背景情况:
- 在阻断的生理作用方面发挥着作用.
- 在稳定的冠状动脉疾病 (CAD) 患者中,补充剂对内皮功能和运动耐受性的影响仍然被低估.
研究的目的:
- 评估口服补充剂对内皮功能和稳定冠状动脉疾病 (CAD) 患者的运动耐受性的影响.
主要方法:
- 一个随机,双盲,安慰剂对照试验,涉及50名稳定的CAD患者超过6个月.
- 使用超声波评估内皮依赖的臂动脉流介导血管扩张 (FMD) 和内皮独立的酸甘氨酸介导血管扩张.
- 通过布鲁斯协议测量了细胞内的度 ([Mg2+) ]和运动耐受性.
主要成果:
- 与安慰剂相比,治疗显著增加了细胞内的度.
- 在的组 (15.5+/-12.0%,P=0.02) 与安慰剂 (4.4+/-2.5%,P=0.78) 相比,观察到干预后口病的显著改善.
- 接受的患者表现出更好的运动耐受性 (9.3+/-2.0对比7.3+/-3.1分钟,P=0.05) 和较少的缺血性ST段变化 (4对比10名患者,P=0.05).
结论:
- 在CAD患者中,口服疗法与腕动脉内皮功能显著改善有关.
- 补充可以增强运动耐受性和减少缺血性变化,这表明它在治疗CAD方面发挥了有益的作用.
- 这些发现表明一种潜在的机制,可以积极影响冠状动脉疾病的临床结果.
相关概念视频
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:26Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
01:20Angina V: Nursing Management
Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...